financetom
Business
financetom
/
Business
/
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion
May 28, 2024 6:45 AM

09:06 AM EDT, 05/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) announced Tuesday it has agreed to acquire the rights to NM26, an experimental eczema treatment, from Numab Therapeutics for $1.25 billion in an all-cash deal.

Price: 147.06, Change: +0.09, Percent Change: +0.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved